TB-500.

Why people discuss TB-500 for recovery

TB-500 is commonly discussed alongside BPC-157 for injury recovery. The proposed connection to tissue repair comes partly from research on the longer protein thymosin beta-4; that is not the same as evidence that a TB-500 product repairs an injury in a person. See the BPC-157 and TB-500 comparison.

Follow the identity and evidence through TB-500 versus thymosin beta-4.

For the proposed role of each ingredient and the evidence behind it, see how GLOW and KLOW are meant to work.6

A name can hide a formulation question

TB-500 is often described as a thymosin beta-4 fragment, but seller labels do not establish sequence, salt, concentration, sterility or identity. A laboratory result for thymosin beta-4 or another fragment cannot automatically be transferred to an online TB-500 product. See storage claims, product quality and travel for practical context.

For tested sport, check peptides and anti-doping rules.12

Is TB-500 the same as thymosin beta-4?

In its 2026 assessment, FDA describes the TB-500 free-base substance it evaluated as a synthetic, chemically modified fragment containing seven amino acids from the 43-amino-acid thymosin beta-4 molecule. FDA notes that different salts and derivatives have been sold under the same common name. Related molecules are not automatically interchangeable: their structure, formulation and route may change their effects. An online label alone does not verify that a vial contains the substance described in a research paper. Thymosin alpha-1 is a different peptide; see the thymosin name comparison.4

What do human studies of the longer molecule show?

One 2015 randomised study assigned 72 people with dry eye to an investigational thymosin beta-4 eye solution or placebo for 28 days. Neither of its two primary measures differed significantly between groups at the prespecified assessment, although some secondary measures favoured the solution. It studied the longer molecule as eye drops, not injected TB-500 for injury recovery. At its July 2026 review, FDA said it had not identified clinical studies or human exposure data for TB-500 by any route; that is a finding of its search at that time, not proof no human has ever used it. Follow the larger thymosin beta-4 eye trials and what they mean for TB-500.34

What would count as evidence

A useful answer would require a defined product, a suitable comparator, patient-important recovery outcomes and active collection of harms. Testimonials and before-and-after photographs cannot separate a peptide effect from natural recovery, co-interventions or selection. Explore how trials compare treatments, how research moves from laboratory models to people.

Why injection quality matters

Regulators warn that unapproved injectable products may have unknown identity, sterility, concentration or contaminants. ‘Research use only’ is a marketing label, not evidence that a product is suitable for people. This page does not provide sourcing or injection instructions.12

In its July 2026 assessment, FDA identified limited information about TB-500’s identity and impurities and raised concern that peptide impurities and aggregation could increase the risk of immune reactions with injectable products. It had not identified clinical studies assessing these risks. This does not establish that every product has the same defect. For symptoms and when to get help, see injection-site reactions.6

U.S. compounding policy: a narrow interim position

In October 2026 HHS published a draft interim enforcement-discretion policy covering specified forms of BPC-157, TB-500, KPV, epitalon, MOTS-c and Semax in section 503A compounding. Its Appendix B identifies the chemical form and routes addressed for each peptide; the policy also describes conditions including a patient-specific prescription, ingredient characterization and a single active ingredient. It is a statement of enforcement intent, not FDA approval or proof of safety or effectiveness; it does not establish the legality or quality of an online vial or a multi-ingredient stack. Read the peptide overview and the linked HHS policy for the specific conditions. Checked 5 November 2026. For the conditions and the separate 2027 advisory discussion, see the US policy guide.5

Development & regulatory context

These selected records are not a complete global legal-status list. Approval depends on the product, use, population and country; check each record’s date.